Date Insider Type Main position Quantity % Market Cap. Importance
23/10/23 Free

General Counsel

70,000 0.7479%
16/10/23 Free

Chief Financial Officer

151,416 1.6178%
15/9/23
Versi Group LLC
ConversionCompany 729,200 7.7913%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-99.00% - - 10
-0.12%-3.34%+46.16%+130.20% 1,216B
-0.14%-0.78%+44.98%+78.68% 656B
-0.19%-2.44%+31.35%+103.76% 509B
-1.70%-4.66%+45.02%+62.18% 384B
-0.44%-1.93%+70.94%+40.53% 362B
-1.33%-1.18%+29.71%+56.93% 311B
-1.70%-1.22%+7.45%+34.20% 293B
-0.31%-1.76%+45.06%+67.79% 249B
-0.07%-2.03%+35.50%+106.08% 208B
Average -10.48%+0.60%+39.57%+75.59% 465.31B
Weighted average by Cap. -0.49%+0.03%+41.68%+87.86%
Logo DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Employees
12
  1. Stock Market
  2. Stocks
  3. DMKPQ Stock